{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Oncologic+Disorders&page=22",
    "query": {
      "condition": "Oncologic Disorders",
      "page": 22
    },
    "page_size": 10
  },
  "pagination": {
    "page": 22,
    "page_size": 10,
    "total_count": 752,
    "total_pages": 76,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Oncologic+Disorders&page=23&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Oncologic+Disorders&page=21&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-23T20:58:14.553Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04305613",
      "title": "Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated With Chemoradiation Therapy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cardiotoxicity",
        "Lung Cancer Stage III",
        "Lung Cancer Stage II",
        "Radiation Toxicity"
      ],
      "interventions": [
        {
          "name": "Chemoradiation",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Abramson Cancer Center at Penn Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 221,
      "start_date": "2020-09-14",
      "completion_date": "2030-12",
      "has_results": false,
      "last_update_posted_date": "2026-10-05",
      "last_synced_at": "2026-10-23T20:58:14.553Z",
      "location_count": 8,
      "location_summary": "Birmingham, Alabama • Boston, Massachusetts • St Louis, Missouri + 5 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04305613"
    },
    {
      "nct_id": "NCT04273724",
      "title": "Early Intervention for Impairments Identified During Comprehensive Geriatric Assessment in Patients With Bladder Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "Targeted Interventions for Impairments Identified During Geriatric Assessment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "UNC Lineberger Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2020-01-21",
      "completion_date": "2021-09-29",
      "has_results": false,
      "last_update_posted_date": "2021-10-18",
      "last_synced_at": "2026-10-23T20:58:14.553Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04273724"
    },
    {
      "nct_id": "NCT03823950",
      "title": "Starting Granulocyte Colony-Stimulating Factor at 1 Day vs 3 Days Following Chemotherapy in Pediatric Cancer Patients",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Granulocyte Colony-Stimulating Factor",
        "Chemotherapy-induced Neutropenia",
        "Chemotherapy-Induced Febrile Neutropenia",
        "Pediatric Cancer"
      ],
      "interventions": [
        {
          "name": "Granulocyte Colony-Stimulating Factor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Mississippi Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 150,
      "start_date": "2019-02-01",
      "completion_date": "2022-06",
      "has_results": false,
      "last_update_posted_date": "2020-03-13",
      "last_synced_at": "2026-10-23T20:58:14.553Z",
      "location_count": 1,
      "location_summary": "Jackson, Mississippi",
      "locations": [
        {
          "city": "Jackson",
          "state": "Mississippi"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03823950"
    },
    {
      "nct_id": "NCT00565721",
      "title": "A Proof-of-concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and Angiogenesis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "High-grade Glioma",
        "Lung Cancer",
        "Head & Neck Cancer",
        "Sarcoma",
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Fluciclatide Injection - (AH111585 (F18))",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GE Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2007-11",
      "completion_date": "2012-09",
      "has_results": true,
      "last_update_posted_date": "2014-08-18",
      "last_synced_at": "2026-10-23T20:58:14.553Z",
      "location_count": 1,
      "location_summary": "Princeton, New Jersey",
      "locations": [
        {
          "city": "Princeton",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00565721"
    },
    {
      "nct_id": "NCT07486713",
      "title": "Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "AML (Acute Myeloid Leukemia)",
        "Glioma",
        "Cholangiocarcinoma",
        "Solid Tumor Malignancies"
      ],
      "interventions": [
        {
          "name": "Olutasidenib",
          "type": "DRUG"
        },
        {
          "name": "CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Probe Substrates",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rigel Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2026-02-23",
      "completion_date": "2027-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-08-11",
      "last_synced_at": "2026-10-23T20:58:14.553Z",
      "location_count": 2,
      "location_summary": "Orange, California • New York, New York",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07486713"
    },
    {
      "nct_id": "NCT04887831",
      "title": "Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Urothelial Carcinoma",
        "Bladder Cancer",
        "Myelosuppression Adult",
        "Chemotherapy-induced Neutropenia",
        "Metastatic Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "Trilaciclib",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Avelumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "G1 Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 92,
      "start_date": "2021-06-04",
      "completion_date": "2024-03-01",
      "has_results": true,
      "last_update_posted_date": "2025-09-08",
      "last_synced_at": "2026-10-23T20:58:14.553Z",
      "location_count": 13,
      "location_summary": "Los Angeles, California • Whittier, California • Littleton, Colorado + 10 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Whittier",
          "state": "California"
        },
        {
          "city": "Littleton",
          "state": "Colorado"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Pensacola",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04887831"
    },
    {
      "nct_id": "NCT03076372",
      "title": "A Study Evaluating MM-310 in Patients With Solid Tumors",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors",
        "Urothelial Carcinoma",
        "Gastric Carcinoma",
        "Squamous Cell Carcinoma of the Head and Neck",
        "Ovarian Cancer",
        "Pancreatic Ductal Adenocarcinoma",
        "Prostate Adenocarcinoma",
        "Non-small Cell Lung Cancer",
        "Small Cell Lung Cancer",
        "Triple Negative Breast Cancer",
        "Endometrial Carcinoma",
        "Soft Tissue Sarcoma"
      ],
      "interventions": [
        {
          "name": "MM-310",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merrimack Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "2017-02-22",
      "completion_date": "2018-12",
      "has_results": false,
      "last_update_posted_date": "2018-02-27",
      "last_synced_at": "2026-10-23T20:58:14.553Z",
      "location_count": 5,
      "location_summary": "Scottsdale, Arizona • San Francisco, California • Rochester, Minnesota + 2 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03076372"
    },
    {
      "nct_id": "NCT03384940",
      "title": "DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Neoplasm"
      ],
      "interventions": [
        {
          "name": "DS-8201a",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daiichi Sankyo Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 86,
      "start_date": "2018-02-23",
      "completion_date": "2020-11-10",
      "has_results": true,
      "last_update_posted_date": "2021-10-18",
      "last_synced_at": "2026-10-23T20:58:14.553Z",
      "location_count": 9,
      "location_summary": "Duarte, California • Los Angeles, California • Santa Monica, California + 6 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03384940"
    },
    {
      "nct_id": "NCT05014399",
      "title": "Cognitive Impairment in Colorectal Cancer Patients Receiving Cytotoxic Chemotherapy",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Neoplasm, Colorectal",
        "Cognitive Impairment",
        "Cognitive Dysfunction",
        "Cognitive Change",
        "Chemo-brain",
        "Chemo Fog",
        "Chemotherapy Effect",
        "Cognitive Decline"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Joseph McCollom",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2021-09-20",
      "completion_date": "2031-10",
      "has_results": false,
      "last_update_posted_date": "2026-08-14",
      "last_synced_at": "2026-10-23T20:58:14.553Z",
      "location_count": 1,
      "location_summary": "Fort Wayne, Indiana",
      "locations": [
        {
          "city": "Fort Wayne",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05014399"
    },
    {
      "nct_id": "NCT01891344",
      "title": "A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Epithelial Ovarian Cancer",
        "Fallopian Tube Cancer",
        "Peritoneal Cancer"
      ],
      "interventions": [
        {
          "name": "Oral rucaparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "pharmaand GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 491,
      "start_date": "2013-10-30",
      "completion_date": "2021-09-28",
      "has_results": true,
      "last_update_posted_date": "2023-06-12",
      "last_synced_at": "2026-10-23T20:58:14.553Z",
      "location_count": 36,
      "location_summary": "Anchorage, Alaska • Tucson, Arizona • Fullerton, California + 28 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01891344"
    }
  ]
}